Corbus begins Resunab’s Phase II trial for Dermatomyositis

Corbus Pharmaceuticals Holdings has enrolled the first patient in its phase II clinical trial, which will assess the safety and efficacy of Resunab to treat Dermatomyositis, a rare and inflammatory muscle disease accompanied by skin rashes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news